Although fluorescence imaging plate reader (FLIPR)-based assays have been widely used in high-throughput screening, improved efficiencies in throughput and fidelity continue to be investigated. This study presents an offline compound addition protocol coupled with a testing strategy using mixtures of compounds in a 384-well format to identify antagonists of the neurokinin-1 receptor expressed in the human astrocytoma cell line (U373 MG). Substance P evoked a concentrationdependent increase in intracellular cellular Ca 2+ with an EC 50 value of 0.30 ± 0.17 nM, which was inhibited by neurokinin-1 (NK1) antagonists L-733,060 and L-703,606. Test compounds, as mixtures of 10 compounds/well, were added to the cells offline using an automated dispensing unit and incubated prior to performing the assay in the FLIPR. Using the offline protocol, a higher throughput of~200,000 compounds was achieved in an 8-h working day, and several novel structural classes of compounds were identified as antagonists for the NK1 receptor. These studies demonstrate that the offline compound addition format using a mixture of compounds in a 384-well FLIPR assay provides an efficient platform for screening and identifying modulators for G-protein-coupled receptors. (Journal of Biomolecular Screening 2005:46-55) 
INTRODUCTION
G -PROTEIN-COUPLED RECEPTORS (GPCRs) are the largest known family of cell surface receptors, with~40% to 50% of the marketed drugs directly or indirectly modulating GPCR function. Those receptors coupled to Gq proteins increase the intracellular calcium upon activation. Receptor activation by agonists simulates phospholipase C β, which leads to the hydrolysis of phosphatidylinositol 4,5 diphosphate to generate inositol triphosphate (IP 3 ) and diacylglycerol (DAG), with the resultant release of intracellular stores of calcium. Agonist-evoked changes in intracellular calcium can be easily detected by calcium-sensitive dyes using the fluorescent imaging plate reader (FLIPR; Molecular Devices, Sunnyvale, CA), and accordingly, FLIPR-based calcium assays have been widely used in high-throughput screening (HTS) to identify modulators of GPCRs. 1 In typical FLIPR assay formats, cells are loaded with the acetoxymethyl ester of fluo-4 (or its analog, fluo-3), and the extracellular unincorporated dye is removed by repeated washing. Upon cellular uptake, acetoxymethyl ester gets cleaved by cellular esterases to liberate fluo-4; the latter, upon binding to intracellular Ca 2+ , increases fluorescence, which can be detected at excitation and emission wavelengths of 488 nm and 520 nm, respectively. Recent modifications of Ca 2+ -sensitive dyes have eliminated the need for removal of the unincorporated dye from the extracellular media by the incorporation of a quencher dye. This eliminates background fluorescence, and the signal evoked from the cells can be detected with a higher resolution. 2 A major practical benefit of this method is that it eliminates the cell-washing step, resulting in easier automation and faster screening throughput. This article reports adaptation of the methodology by employing an offlineaddition format for identifying antagonists of a G-protein-coupled receptor, exemplified by neurokinin-1 (NK1) receptor. NK1 receptors, the preferential target class for the mammalian tachykinin substance P, are widely distributed, with higher localization primarily in neurons within the CNS. The NK1 receptor couples via guanine nucleotide Gq proteins and is a readily amenable target class for HTS. Substance P plays a key role in pain transmission pathways; therefore, NK1 receptor antagonists were initially considered as a useful therapeutic approach for pain. However, later evidence has suggested that NK1 receptor antagonists may also be useful as antidepressants and anxiolytic agents. 3, 4 Although there have been previous attempts to exploit the development of small-molecule antagonists for the NK1 receptor in di-verse neuronal indications, there is limited clinical validation of the target. This may be attributed to various factors, including species variation in the NK1 receptor pharmacology and the poor ability of compounds to cross the blood-brain barrier. Therefore, there is still a need to identify ideal antagonist leads for this target.
In this study, we employed a protocol involving the offline addition of compounds to identify NK-1 receptor antagonists in U373 MG cells using the FLIPR calcium assay kit. Screening was performed using compound mixtures in a 384-well format to further enhance the throughput. Mixing of compounds into pools is an effective way to accelerate the screening process and reduce costs. Compounds were added to a cell plate using an offline protocol with an automated liquid dispensing system and incubated with cells prior to performing the FLIPR assay. Results from the offlineaddition format were compared to the traditional FLIPR doubleaddition protocol using a subset of 9600 compounds. Using the offline protocol, a throughput of approximately 100 plates was achieved in an 8-h working day (~200,000 compounds in duplicate/8 h), leading to the identification of several structural classes of compounds as antagonists for the NK1 receptor. The advantages of the offline format, such as higher throughput, identification of weaker inhibitors, reduction of fluorescent artifacts, and identification of agonists and antagonists in a 1-step assay protocol, are discussed in this study.
MATERIALS AND METHODS

Materials
Cell culture reagents were purchased from Life Technologies BRL (Gaithersburg, MD). The calcium assay kit was purchased from Molecular Devices (Sunnyvale, CA). Fluo-4 was purchased from Molecular Probes (Eugene, OR). The NK1 receptor ligands, substance P, [Sar 9 , Met (O2) 11 ]-substance P, GR73632, L-733,060 (3-((3,5- 
Cell culture
U373 MG cells (ATCC) were grown to confluency in 162-cm 2 tissue culture flasks in modified Eagle's medium Glutamax I, supplemented with 10% fetal bovine serum (FBS) and 1% nonessential amino acids (NEA) and 50 µg/mL gentamicin. The cells were dissociated from the flasks using trypsin, and 20 µL of 3 × 10 5 cells/mL cell suspension was plated (6000 cells/well) using a 384well Multidrop (Thermo Labsystems, Helsinki, Finland) into plates and maintained 48 h in a tissue culture incubator at 37°C under an atmosphere of 5% CO 2 .
Fluorescence measurements
Changes in intracellular Ca ++ were determined using calcium assay kits (Molecular Devices, Sunnyvale, CA). A 10× stock solution of the dye was prepared by dissolving each vial supplied by the vendor in 10 mL of Hank's balanced salt solution buffer (HBSS from Invitrogen) with 20 mM HEPES. Before use, the stock solution was diluted 1:10 using the same buffer. Probenecid was solubilized in 1.0 NaOH and mixed with an equal volume of HBSS buffer to get a stock solution of 250 mM. A fresh stock of probenecid was made each day and added to the dye solution to attain a final concentration of 2.5 mM. The diluted dye (20 µL) was loaded into the cells containing media and incubated at room temperature for 60 min. Then, the test compounds or buffer (20 µL) were added into the cell plate using a PlateMate Plus liquidhandling unit (Matrix Technologies Corp., Hudson, NH) and moved to FLIPR for the addition of substance P (20 µL) using the FLIPR liquid-handling device. The fluorescence measurements were read simultaneously from all the wells at an excitation wavelength of 480 nm and an emission wavelength of 520 nm. A baseline fluorescence signal was measured for the first 10 sec, after which 20 µL of 4× concentration of substance P was added to the cell plate. The changes in fluorescence intensity were measured every second for the first 1 min, followed by every 5 sec for an additional 1 min. For the double-addition protocol, compounds were added by the FLIPR after the baseline measurement, and the readings were taken for a period of 3 min, followed by the addition of substance P, as described above. IC 50 determinations were done using the double-addition protocol in FLIPR. Compounds were diluted 1:10 from 100 µM (final concentration) across 6 wells. Fluorescent measurements were taken as described above.
For experiments using fluo-4, media were removed from the cells and incubated with fluo-4 in HBSS/HEPES. Stock solution of the dye was prepared in anhydrous DMSO and further diluted in the HBSS/HEPES buffer containing pluronic acid (0.025% w/v) to attain a final dye concentration of 2.5 µM. Then, 40 µL of dye solution containing 2.5 mM probenecid was loaded into each well and incubated for 90 min at room temperature. Unincorporated dye was removed from the cells by washing the cell plates with the assay buffer and replacing with 40 µL of the original buffer.
Data analysis
Fluorescence responses were corrected to the background changes in fluorescence and normalized to the response observed with the reference agonist, substance P (100% assigned to the maximum increase in fluorescence units). Percent response of the agonist was calculated based on the response to 1 µM substance P, which was defined as 100%. For antagonists, percent inhibition of the wells was normalized to the response of substance P at 0.75 nM (100% assigned to this response). Concentration-response data
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were fitted with sigmoidal curves generated by nonlinear regression analysis (GraphPad Prism, San Diego, CA) to obtain EC 50 or IC 50 values. Data were expressed as mean ± standard deviation (SD). For the HTS screen, the maximum absolute change in signal of the substance P response was exported into a customized spreadsheet, which calculated the percent inhibition of each well based on the median signal of each plate and generated an analyzed data file in a string format. This file was loaded into an Oracle database, which plots the scatter plot of each task and allows picking of the hits.
RESULTS AND DISCUSSION
Characterization of endogenous NK1 receptors in U373 MG cells
Addition of substance P resulted in a rapid increase in fluorescence and reached a peak value within 10 to 20 sec, followed by a decline to near the basal level within 60 sec. Initially, experiments were performed with substance P diluted in HBSS/HEPES buffer using the calcium assay kit. Substance P evoked a concentrationdependent increase in fluorescence with an EC 50 value of 3.3 ± 1.9 nM, with a maximal response occurring at 300 nM. In the presence of 0.1% bovine serum albumin (BSA), the EC 50 value of substance P was 0.30 ± 0.17 nM, and a maximal response was observed at a substance P concentration of 30 nM (Fig. 1A,B ). This EC 50 value is comparable to the equilibrium-binding constant derived for the NK1 receptor in U373 MG cells using 125 I-Bolton Hunter substance P. 5 It is likely that the substance P is hydrophobic and adheres to the plastic used in the experiment, and the presence of BSA reduces nonspecific binding of substance P. Therefore, 0.1% BSA was included in all subsequent experiments.
Experiments carried out with fluo-4 in the presence of 0.1% BSA produced similar concentration-response curves for substance P, with an EC 50 value identical to the results obtained using the calcium assay kit. With fluo-4, both the kinetics and the quantum yield of fluorescent response were similar to the calcium assay kit ( Fig. 2 ). Because there is no washing step involved with the calcium assay kit, it reduced the number of steps in the assay, leading to greater throughput compared to fluo-4. Therefore, the NK1 HTS screen was further developed using the calcium assay kit. Other known NK1 agonists, such as GR73632 and [Sar 9 , Met (O2) 11 ]-substance P, yielded EC 50 values of 16.6 ± 1.6 nM and 0.53 nM ± 0.1 nM, respectively, with the calcium assay kit ( Fig. 3) .
Initial experiments without the inclusion of probenecid showed a lower signal compared to experiments with probenecid (data not shown). Therefore, probenecid was included for all further experiments. The presence of FBS or phenol red in the medium did not influence the assay (data not shown), and accordingly, the dye was added directly to cells containing media. It is important to note that optimization of various parameters in the FLIPR was critical for the robustness of the assay. All the experiments were carried out with an f-stop of 1. intensity was adjusted for every plate to a basal signal of 12,000. This yielded a net calcium response between 30,000 and 40,000 fluorescence units. Routinely, cells were loaded with the dye for at least 60 min. However, loading the cells with the dye for a period of up to 180 min did not show any deleterious effect on cells or change the EC 50 of substance P. Because substance P was dissolved in buffer containing 0.1% BSA, an aspiration speed of 5 µL/sec was chosen in the FLIPR, which minimized bubble formation in the pipette tips; the speed of the addition of substance P into the cell plate was 20 µL/sec.
Antagonist concentration response curves
L-733,060 and L-703,606 inhibited the Ca 2+ release evoked by substance P in a concentration-dependent manner, with IC 50 values of 16.5 ± 5 nM and 88 ± 20 nM, respectively, in the offline-addition protocol (Fig. 4) . These compounds displayed similar IC 50 values when tested in the double-addition protocol. The IC 50 values of the compounds were converted to K i values by the Cheng-Prusoff equation: 6, 7 
where [A] is the agonist concentration, and EC 50 is the agonist EC 50 .
The K i values of L-733,060 and L-703,606 were 4.7 and 25 nM, respectively, which correspond with the values previously reported for these antagonists for inhibiting substance P-induced calcium release. 8 Other antagonists, such as WIN 51,708 and WIN 62,577, did not inhibit the NK1 receptor-mediated Ca 2+ release in U373 MG cells. WIN 51,708 attenuates the formation of inositol phosphate predominately by activating NK1 receptors in primary cultures of neonatal rat spinal cord. 9 WIN 51,708 and WIN 62,577 are competitive antagonists at the tachykinin NK1 receptor and have shown species-selective interactions that are more potent in rat than in guinea pig or human tissues. 10 U373 MG cells are human astrocytoma cells, and the inactivity of these compounds confirms the observation of species-dependent activity of these compounds. 11
Optimization of assay for HTS
Titration of varying concentrations of substance P (0.25, 0.5, 0.75, and 1 nM) was performed to determine the optimal agonist concentration for the screen. It was observed that the coefficient of variation (CV) for the plate was ≤10%, with a substance P concentration of ≥0.75 nM. At substance P concentrations of 0.5 nM and 0.25 nM, the CV increased to 17% and 25%, respectively. Therefore, a concentration of 0.75 nM was selected for screening, which is about 2.5-fold higher than the EC 50 value. The relative fluorescence signal of a 384-well plate containing 0.75 nM substance P versus buffer controls is shown in Figure 5A . These conditions provide an excellent Z′ value of 0.71 (± 0.12). A scatter plot showing percent inhibition of each well from the same plate is shown in Figure 5B . DMSO is routinely used to solubilize compounds in the chemical library; therefore, the effect of DMSO on fluorescence signals was evaluated. DMSO was tested at final concentrations ranging from 0.5% to 5% (v/v). Increasing the concentration of DMSO from 2% to 5% produced a concentration-dependent decrease in relative fluorescence, whereas no interference was observed at 1% DMSO (Fig. 6) . Therefore, the DMSO concentration was maintained at 1% throughout the screen.
Screening was performed with 384-well mixed-compound plates containing 10 compounds/well at a screening concentration of 1 µM of individual compound. Test compounds were formatted using a 10 × 10 orthogonal mixing strategy, with each compound present twice with 9 other unique compounds in wells. 12 This strategy facilitates the identification of active compounds in HTS by the deconvolution of signals from wells that score positive. The compound concentration used in the HTS was determined by testing a mixed-compound plate containing discrete compound con- centrations of 1, 2.5, and 5 µM. The Z factor values for 1, 2.5, and 5 µM were 0.51, 0.36, and 0.13, respectively. Although the individual concentration of each compound/well was 1, 2.5, and 5 µM, the cumulative compound concentration/well was 10, 25, and 50 µM, respectively. This may account for the drastic changes in the Z factor value with increasing concentrations. A compound concentration of 1 µM was chosen for the screen, which generated a Z factor ≥0.5, indicating that this assay is robust enough for an HTS. Because the HTS is done using a mixture of compounds, it is a routine practice to spike a reference compound in a concentration-dependent fashion and determine the IC 50 value of the compound in the presence of 10 other compounds. Therefore, the reference antagonists L-733,060 and L-703,606 were spiked into the compound plate, and the IC 50 values were 12.8 ± 10.60 nM and 51.71 ± 21.49 nM, respectively (n = 6). These values agree with the IC 50 value of these reference agonists tested as a single compound/well. This validated the strategy of using mixture compounds for HTS.
Offline-Addition Format for Identifying GPCR Modulators
As a part of the validation protocol, a subset of 9600 compounds was tested for antagonist activity in the FLIPR using the offline-addition method. Typically, for every assay, we initially test a pilot set of 9600 compounds, followed by retest of the picks and determination of the IC 50 values of the hits. This would enable one to gauge the performance of the screen, such as hit rate, robustness, and so on, prior to starting the entire screen. The scatter plot for a subset of compounds done by the offline format is shown in Figure  7A , and the compounds with confirmed IC 50 values are highlighted. The same collection of compounds was also tested using the FLIPR double-addition protocol. The scatter plot is shown in Figure 7B . The scatter is similar for both formats, but the offline protocol identified more active compounds compared to the double-addition method. In addition, confirmed compounds showed a lower percent inhibition in the primary screen in the double-addition protocol as compared to the offline addition. A total of 8 compounds with IC 50 values of ≤20 µM were identified A B from this pilot set with a hit rate of 0.08%. Six compounds were common to both formats (IC 50 values ranging from 1-10 µM), and 2 compounds were uniquely identified by the offline-addition method (2 µM and 15 µM). The offline protocol enabled the compounds to incubate with the cells for a longer period of time compared to the shorter incubation time (typically 3 min) using the FLIPR double-addition protocol. The longer incubation of compounds in the offline protocol may contribute to the identification of weaker inhibitors, although we have not explored the mechanism in more detail in this study. Because the offline-addition protocol identified additional compounds and enhanced assay throughput, it was selected as the method of choice for the HTS. Primary screening and retest were done using the offline-addition protocol, and the IC 50 determination was carried out with a doubleaddition protocol to distinguish the antagonists from the agonists.
Following the validation of the assay, an HTS assay was initiated using an offline-addition method with a throughput of approximately 200,000 compounds per day. A batch of 20 plates was loaded with dye and incubated for 1 h, and the test compounds were dispensed to 5 plates at a time and then manually loaded into the FLIPR stacker. Briefly, the offline addition of compounds was coordinated with FLIPR screening such that each cell plate was incubated with compounds for 15 min prior to substance P addition. Because the compounds were added offline, the FLIPR time for each plate was less than 3 min, and a throughput of 20 plates was achieved per hour (~48,000 compounds/h). The entire primary screen of~633,600 Abbott library compounds was completed in 3 days. To eliminate plate-to-plate variations in signals, the percent inhibition in each well was calculated from the median response of substance P in each plate, which was considered as a 100% response. To further eliminate potential addition effects in each well, the max -min fluorescent signal was assessed, and percent inhibition was calculated as follows: The scatter plot of each plate was evaluated, and any hits above 30% inhibition were selected for retesting. From the primary screening of~633,600 compounds, approximately 26,000 compounds were selected for retesting (~4% pick rate). In the FLIPR software, subtract bias and spatial uniformity correction were turned off, and thus wells containing fluorescent compounds were identified based on their higher basal signals. In some instances, the effects of fluorescent compounds caused blooming into adjacent wells. Based on the kinetic cellular responses and the fluorescent evaluation of the compound plate, wells containing the fluorescent compounds were eliminated for further evaluation, and the inhibited adjacent wells were picked for retesting. The effect of fluorescent compounds in a 384-well format FLIPR assay is discussed in detail later. Retesting of picks was done in duplicate in 384-well plates as single compounds at a final concentration of 10 µM. Because the hit rate in the assay was found to be low in the initial validation of 9600 compounds Well Number
(0.08%), an aggressive picking strategy was employed to find weaker hits in the screen. Compounds selected from retesting were evaluated for IC 50 determinations from a starting concentration of 100 µM; 246 compounds displayed IC 50 values <100 µM, as summarized in Table 1 . Overall, the hit rate of the screen was relatively low (~0.04%). Approximately 48% of the hits had IC 50 values ranging from 10 to 100 µM, and 43% of the compounds had IC 50 values in the 1-to 10-µM range. Twenty-three compounds (~9%) displayed IC 50 values less than 1 µM. Among the 246 compounds identified as hits from the primary screen, only 2 compounds were discovered to be agonists. The agonists were differentiated from antagonists using a double-addition protocol at the IC 50 stage. In the offline protocol, a specific NK1 receptor agonist would cause receptor desensitization and would appear as a hit in the antagonist screen. The property of agonists as hits in an antagonist screen, as demonstrated by the reduction of agonist response, is investigated and discussed later. Although compounds were screened at 1 µM, a number of weak (high µM IC 50 s) were identified. Eight diverse structural classes of compounds with IC 50 values ranging from 0.06 to 2 µM were identified.
Effect of fluorescent compounds
One additional advantage to the offline method was the pronounced reduction of fluorescent compounds compared to the double-addition procedure. To further investigate this phenomenon, we tested a 384-well compound plate containing a collection of several known fluorescence compounds in both formats. In the double-addition protocol, the signal from the fluorescent compounds obscured the signal from adjacent wells, resulting in spurious results in the particular plate (Fig. 8A ). This is a typical artifact observed in FLIPR assays, especially in a 384-well plate, when the CCD camera chip images highly fluorescent compounds. 13 Under conditions in which a CCD camera chip is exposed to very highintensity illumination, saturation of the storage capacity of the CCD occurs, a condition known as blooming. When this happens, excess charge overflows into the adjacent CCD photodiode in the chip, corrupting the image near the blooming site. This will bleed down a diode column during a readout, causing false spikes in the adjacent wells. The fluorescent compounds in the plate were located in wells E2, K4, O6, O14, and G22. In the double-addition method, wells vertically adjacent to the well containing fluorescent compounds were affected by blooming. The same compound plate tested using the offline protocol exhibited less interference from fluorescence compounds (Fig. 8B) . The effects of fluorescent compounds were mainly localized to the individual wells, and minimal cross-talk to the adjacent wells was observed. In the double-addition protocol, the CCD camera is exposed to a high local concentration of fluorescent compounds during the addition process. The bolus of compound saturates the camera pixels and results in blooming. However, in the offline-addition protocol, the camera is exposed to the compounds after the dilution and mixing of the compounds with the cells. The effect of fluorescent com-pounds on the FLIPR CCD camera image (fid file) is shown in Figure 8C , D.
It was noticed that for an HTS of more than 600,000 compounds, offline addition rescued the data from wells that are adjacent to the wells containing the fluorescent compound. We also compared the effects of fluorescent compounds for 2 different GPCR targets using the same dye and at the same screening concentration of compounds (1 µM). The data clearly show that the blooming effect of compounds was more pronounced in the double-addition format screen compared to the offline screen. In the double-addition protocol, approximately 3 times more wells were affected by blooming compared to the offline format. It should be noted that these studies were done at a screening compound concentration of 1 µM, and one would anticipate more interference at higher compound test concentrations.
Receptor desensitization
The offline protocol offers an advantage of identifying antagonists and specific agonists using 1 addition protocol in FLIPR. As with other G-protein-coupled receptors, the NK1 receptors are prone to desensitization following exposure to agonists. 14 To test this desensitization phenomenon for NK1 receptors, we first treated U373 MG cells with various concentrations of NK1specific agonists, followed by a second challenge of substance P (0.75 nM) after a 15-min incubation period ( Fig. 9 ). NK1-specific agonists, substance P, and GR73632 resulted in a concentrationdependent increase in calcium, with EC 50 values of 0.26 nM and 9.8 nM, respectively, in this experiment (Fig. 9A) . A decrease in response to the concentration of substance P (0.75 nM) in the second challenge was observed, and the percent inhibition of response was directly related to the concentration of agonist in the first challenge. The EC 50 values of agonists in inducing the desensitization response with 0.75 nM concentration of substance P were 0.38 nM and 14 nM, respectively (Fig. 9B) . Thus, the inhibition of calcium response in the second challenge was proportional to the EC 50 value of the corresponding agonist in the first challenge.
Histamine elicits concentration-dependent calcium mobilization, with an EC 50 value of 200 nM by activation of H1 receptors endogenously expressed in U373 MG 15 cells (Fig. 9A) . To assess the phenomenon of cross-desensitization, we exposed cells to varying concentrations of histamine initially (0.01 nM to 1 µM), followed by challenge with substance P (0.75 nM). The response of substance P was not inhibited by the pretreatment with histamine, suggesting that NK1 receptor desensitization is a receptordependent process and that receptor desensitization occurs only by the addition of the receptor-specific agonists. This experiment confirms that an offline-addition protocol can pick up both antagonists and specific agonists. Therefore, it reduces the inconvenience of analyzing the data twice for the agonist and the antagonist. However, in an antagonist assay for a receptor target with several specific agonists in the screening library, the number of retests and IC 50 tests needed to be done to distinguish the antagonists from agonists will be substantial. There are considerable time and cost savings in the HTS using compound mixtures. Pooling of compounds is a feasible option, with the assumption that only very few compounds in the library are active against a particular target. However, one could have concerns regarding the mixture artifacts, such as the additive or synergistic effect of compounds, the presence of agonists and antagonists in the same well, and the presence of fluorescence compounds interfering with detecting the activity of other wells. Pooling by dissimilarity avoids most of these problems, but screening in duplicate where there are individual compounds with separate entities in each pool will decrease the chance of missing potential hits. Each compound is screened twice in the library, with 9 different unique compounds in each well. Even if the activity of a compound is obscured in 1 well location, the compound will be identified in the other. The effects of fluorescent compounds were diminished significantly in the offline format, permitting the screening of mixtures in the 384-well format. One of the limitations with a cell-based functional assay using mixtures is the concentration of compounds. Ideally, a compound concentration of 10 µM would be used for screening a single compound in the FLIPR. Due to the mixture strategy, the FLIPR 384-well format using mixtures is limited to an individual compound concentration of 1 to 2 µM, which is 10 to 20 µM of cumulative compound concentration/ well. Although 384-well mixed-compound screening is limited to 1 to 2 µM, a substantial number of compounds in the IC 50 range of 10 to 100 µM are picked up from the NK1 screen.
Conclusions
A robust HTS assay was developed using U373 MG cells by employing an offline-addition format for identifying antagonists of the NK1 receptor using the calcium assay kit. Although NK1 has been explored for at least a decade as a target for neuronal indications such as pain and depression, clinical validation has been hitherto hampered by several factors. A need to identify antagonist leads for this target still exists, which has been enabled in this study by expeditious screening of our compound collection. More than 600,000 low-molecular weight compounds were screened in duplicate, and several structural classes of antagonists were identified. The assay was found to be robust and reproducible, with a screen throughput of~200,000 compounds in 8 h. The addition of compounds in an offline format resulted in higher throughput and enabled identification of even weak inhibitors and agonists. In addition, the offline format minimized the interference from fluorescent compounds compared to the standard double-addition protocol. The identification of a diverse collection of novel smallmolecule NK1 receptor antagonists could facilitate the characterization of these receptors in the in vitro and in vivo models and give further insights regarding their role in indications such as pain and schizophrenia. 
